ATR Inhibitors in Platinum-Resistant Ovarian Cancer

Area of Science:

• Oncology
• Molecular Biology
• Genetics

Background:

• Platinum-resistant ovarian cancer (PROC) presents a significant clinical challenge with a median overall survival (OS) under 12 months.
• Current targeted therapies like bevacizumab and poly (ADP-ribose) polymerase inhibitors (PARPi) offer some benefit but novel approaches are needed.
• Ataxia telangiectasia and RAD3-Related Protein Kinase inhibitors (ATRis) are emerging as a promising targeted therapy class.

Purpose of the Study:

• To review the anticancer mechanisms of ATRis.
• To summarize the current research progress and clinical efficacy of ATRis in treating PROC.
• To highlight ATRis as a potential therapeutic strategy for PROC.

Main Methods:

• Literature review of preclinical and clinical studies on ATRis in PROC.
• Analysis of the molecular mechanisms of ATRis, including cell cycle regulation and homologous recombination (HR) repair.
• Synthesis of data on the efficacy and safety of ATRis in PROC treatment.

Main Results:

• ATRis demonstrate efficacy in preclinical and clinical settings for PROC.
• These inhibitors target key pathways involved in cancer cell proliferation and survival.
• Research indicates ATRis can modulate homologous recombination repair, a critical process in ovarian cancer.

Conclusions:

• ATRis represent a promising targeted therapy for platinum-resistant ovarian cancer.
• Further clinical investigation is warranted to establish the role of ATRis in PROC treatment paradigms.
• Understanding ATRi mechanisms can guide the development of more effective cancer therapies.